Please assess the completion status of the following clinical trial:

Trial Title: Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed MS according to the IDF criteria:~* - - Waist circumference: ≥80 cm (women) ≥90 cm (men), plus two or more of the following:~* - - - - Fasting glucose ≥ 100 mg/dL~* - - - - Triglycerides ≥150 mg/dL~* - - - - HDL-C: Men ≤40 mg/dL, women ≤50 mg/dL~* - - - - Blood pressure ≥130/85 mmHg~* Body Mass Index between 25 and 34.9 kg/m²~* No pharmacological treatment for MS~* Stable weight during the last 3 months~Exclusion Criteria:~* Pregnancy or breast-feeding~* History of kidney or liver disease~* Drugs or supplements consumption with proven properties that modify the behavior of the MS~* Total cholesterol \>240 mg/dL~* Triglycerides \>500mg/dL~* Glucose ≥126 mg/dL or HbA1C ≥6.5%.~* Hypersensitivity to Fucoxanthin

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Fucoxanthin (Type: EXPERIMENTAL): 12 mg Fucoxanthin capsule, once a day before breakfast during 90 days.
- Placebo (Type: PLACEBO_COMPARATOR): Homologated magnesium sterate capsule, once a day before breakfast during 90 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).